These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 1560703)

  • 1. [The 1990 drug law. Its implications for the clinical doctor].
    Castillo Pérez P; Gutiérrez López JF
    Med Clin (Barc); 1992 Feb; 98(7):263-9. PubMed ID: 1560703
    [No Abstract]   [Full Text] [Related]  

  • 2. International reporting on adverse drug reactions: the CIOMS project. CIOMS ADR Working Group.
    Faich GA; Castle W; Bankowski Z
    Int J Clin Pharmacol Ther Toxicol; 1990 Apr; 28(4):133-8. PubMed ID: 2338366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The case for preemption of prescription drug failure-to-warn claims.
    Kim CH
    Food Drug Law J; 2007; 62(2):399-422. PubMed ID: 17632969
    [No Abstract]   [Full Text] [Related]  

  • 4. Recent developments in pharmaceutical products liability law: failure to warn, the learned intermediary defense, and other issues in the new millennium.
    Garbutt BJ; Hofmann ME
    Food Drug Law J; 2003; 58(2):269-86. PubMed ID: 12866558
    [No Abstract]   [Full Text] [Related]  

  • 5. [Drug monitoring].
    Royer RJ
    Bull Soc Ophtalmol Fr; 1985 Nov; Spec No():11-30. PubMed ID: 4064240
    [No Abstract]   [Full Text] [Related]  

  • 6. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM; Curry JA
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract]   [Full Text] [Related]  

  • 7. [Mandatory report of adverse effects of drugs: has the order modified the spontaneous notification?].
    Haramburu F; Pere JC; Begaud B; Albin H
    Therapie; 1988; 43(6):493-6. PubMed ID: 3227516
    [No Abstract]   [Full Text] [Related]  

  • 8. Medicine goes Madison Avenue: an evaluation of the effect of direct-to-consumer pharmaceutical advertising on the learned intermediary doctrine.
    Allen MC
    Spec Law Dig Health Care Law; 1998 Dec; (236):9-29. PubMed ID: 10187553
    [No Abstract]   [Full Text] [Related]  

  • 9. [Drug regulation in Spain].
    Rubio Terrés C
    Med Clin (Barc); 1992 May; 98(19):741-8. PubMed ID: 1608280
    [No Abstract]   [Full Text] [Related]  

  • 10. [Comparative organization of drug monitoring in France and 7 European countries].
    Vaissere J; de Cremiers F; Auriche M; Juillet Y
    Therapie; 1986; 41(5):369-74. PubMed ID: 3810527
    [No Abstract]   [Full Text] [Related]  

  • 11. Current status of the drug safety monitoring system in Korea.
    Park BJ
    Pharmacoepidemiol Drug Saf; 2001; 10(6):557-60. PubMed ID: 11828840
    [No Abstract]   [Full Text] [Related]  

  • 12. [Detection of side effects. 2: Responsibilities of the pharmaceutical industry, drug commissions, the Federal Health Office and international organizations].
    Gleiter CH; Bieck PR
    Fortschr Med; 1991 Jul; 109(21):429-31. PubMed ID: 1916572
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmaceutical postmarket review: fact or fiction?
    Schanz SJ
    Food Drug Law J; 2007; 62(3):493-500. PubMed ID: 17915391
    [No Abstract]   [Full Text] [Related]  

  • 14. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 15. [4-year experience in drug surveillance].
    Capellà D; Avila P; Cabeza L; Moreno V; Vidal X; Laporte JR
    Med Clin (Barc); 1988 Jun; 91(3):93-6. PubMed ID: 3172912
    [No Abstract]   [Full Text] [Related]  

  • 16. [Minimal information that should be found in reports about suspected adverse reactions of drugs].
    Laporte JR; Lience E
    Med Clin (Barc); 1991 Jun; 97(2):56-7. PubMed ID: 1895784
    [No Abstract]   [Full Text] [Related]  

  • 17. [Drug surveillance and the safety of drugs: guidelines for legislative and total cultural action].
    Laporte JR
    Rev Med Univ Navarra; 1988; 32(1):31-3. PubMed ID: 3175437
    [No Abstract]   [Full Text] [Related]  

  • 18. [The new norms decreed by the legislative dirrective 91-93 CCE].
    Neri M; Palazzo S
    Boll Chim Farm; 1998 Feb; 137(2):31-4. PubMed ID: 9595832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. European commission consultation on pharmacovigilance.
    Waller P; Beard K; Egberts T; Evans S; Hallas J; Hasford J; Laporte JR; Moore N; Shakir S; Sturkenboom M
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):108-9. PubMed ID: 18058839
    [No Abstract]   [Full Text] [Related]  

  • 20. [The Spanish drug surveillance system].
    Laporte JR; Capellà D
    Med Clin (Barc); 1994 Sep; 103(9):335-6. PubMed ID: 7967892
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.